The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On April 14, Cue Biopharma announced that it will receive a $7.5 million milestone payment from Boehringer Ingelheim for the development of the CUE-501 compound. This payment follows the approval of the first compound for lead optimization under their collaboration agreement. The company could earn up to an additional $337.5 million in future milestone and royalty payments.